DexCom, Inc. vs NEOS S&P 500 High Income ETF — how do they compare? DexCom, Inc. trades at $90.17 (market cap $33.79B), while NEOS S&P 500 High Income ETF trades at $54.21. Which is the better fit depends on your goals.
| DXCM | SPYI | |
|---|---|---|
Market Cap | $33.79B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $89.53 | $54.19 |
52-Week Low | $54.84 | $47.98 |
Enterprise Value | $33.24B | — |
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
SPYI trades at $54.19 with a flat 24-hour change, supported by a bullish technical signal from moving averages. The ETF focuses on generating high income through an options overlay on the S&P 500, with recent dividends around $0.53-$0.54 per share. News highlights its 11.7% yield appeal for retirement income, though some articles caution about fee gaps and yield sustainability.
The outlook hinges on volatility-driven income generation, offering tax-efficient distributions but facing risks from declining market volatility and potential principal erosion. Investors are drawn to the high yield for retirement cash flow, yet must weigh the trade-off between income and long-term capital appreciation in a competitive covered call ETF space.
Trailing returns across standard periods
Latest headlines on both assets
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →